The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 348:2259 May 29, 2003 Number 22
NextNext

Selective Estrogen-Receptor Modulators

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Riggs, B. L.
-PubMed Citation
To the Editor: The review article by Riggs and Hartmann on selective estrogen-receptor modulators (SERMs) (Feb. 13 issue)1 does not discuss a SERM approved by the Food and Drug Administration for the treatment of ovulatory dysfunction. Clomiphene citrate has been used extensively for decades.2 It continues to be a first-line drug for the treatment of anovulatory infertility. Clomiphene exerts its effect by binding to estrogen receptors in the hypothalamus and pituitary gland, resulting in increased release of gonadotropins and, in many cases, ovulation and pregnancy.2,3 Many patients have successfully conceived after using this older SERM. It continues to be an . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.